

CITATION REPORT

List of articles citing

Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.

DOI: 10.1080/03007995.2022.2073122

Current Medical Research and Opinion, 2022, , 1-13.

Source: <https://exaly.com/paper-pdf/145255211/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. 2023 , 12, 1775		1
1	The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. 2023 ,		0